Innovative Partnership to Enhance Access in Clinical Trials
Partnership Focused on Patient Access in Clinical Trials
Hawthorne Health, a leader in community trial delivery, has announced an exciting strategic partnership with RxE2, a pioneer in pharmacist-led clinical trial services. This collaboration aims to fundamentally transform the landscape of clinical trial delivery within community settings. By fusing their expertise, they are paving the way for broader patient access and streamlined trial processes.
Building a Network of Community-Based Trial Locations
The alliance leverages Hawthorne Health's extensive network of GCP-trained nurses alongside RxE2's integration of community pharmacists. This creates an impressive integrated network for clinical trials, enabling sponsors to connect with a much larger patient population. The goal is to provide more streamlined logistics and flexible, patient-centered trial options in familiar community settings.
Addressing Clinical Research Challenges
As Josh Rose, CEO of Hawthorne Health comments, patient access and retention are persistent hurdles in clinical research. He emphasizes that the partnership will directly tackle these challenges by delivering trials where patients are most comfortable. By offering flexible trial options, they not only enhance participation rates but also improve data quality, driving overall study success.
A Scalable and Efficient Approach
This partnership combines the best attributes of both organizations, resulting in unmatched efficiency and scalability across clinical trials. By utilizing this unified strategy, they have created a far-reaching community-based network with locations across all 50 states. This significant expansion sets a new benchmark in the industry, redefining clinical trial execution.
The Benefits of Localized Trials
Gerald Finken, CEO of RxE2, stated that this collaboration signifies a major shift in clinical research. By bringing trials directly to local communities, they enhance access while ensuring a supportive environment similar to that of a neighborhood pharmacy. The integration of synergistic services and AI-enabled technologies aims to set a new standard for inclusivity and efficacy in clinical trials.
Contributions to the Annual SCOPE Summit
Both Hawthorne Health and RxE2 will participate in the Annual SCOPE Summit, showcasing their collective innovations. Together with Labcorp, they will present a session titled 'Bridging the Last Mile: A Hybrid Approach to Patient Access and Retention.' This presentation will elaborate on their integrated strategy for patient-centric clinical trial delivery.
About Hawthorne Health
Hawthorne Health has established itself as a leader in community trial delivery, boasting the largest GCP-trained mobile nurse network and access to more than 1,000 community-based locations, such as homes and pharmacies. Their innovative technology prioritizes a patient-centric approach, enhancing access and engagement while ensuring compliance and quality. Their track record includes over 20,000 study visits and 50,000 completed assessments, demonstrating their commitment to advancing clinical outcomes and accelerating therapy development.
About RxE2
RxE2 is reimagining the clinical trial landscape by making it a cost-effective reality. The company's focus on integrating pharmacy practice into clinical trials empowers community pharmacists to leverage their patient insights, thereby enhancing accessibility. As trusted medication experts, pharmacists streamline clinical trial timelines and costs, improving outcomes for both study sponsors and patients. Their model facilitates productive collaborations with sponsors and CROs, while offering pharmacists a centralized access point for all clinical trial-related services.
Frequently Asked Questions
What is the goal of the partnership between Hawthorne Health and RxE2?
The partnership aims to expand patient access to clinical trials while streamlining logistics and providing flexible, community-based options for participants.
How does this partnership benefit patient participation?
By offering trials in local and trusted environments, the partnership improves accessibility and retention rates, leading to higher-quality data and better study outcomes.
What makes the integrated approach of Hawthorne Health and RxE2 unique?
The collaboration combines the expertise of GCP-trained nurses and community pharmacists, creating the largest network of clinical trial locations across the country.
When and where will the upcoming presentation take place?
The presentation at the Annual SCOPE Summit will occur on February 5 and will detail their approach to patient access and retention in clinical trials.
What has been the impact of Hawthorne Health's work so far?
With over 20,000 study visits and successful audits, Hawthorne Health's efforts have significantly improved clinical trial outcomes and accelerated the development of new therapies.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
